Biotech firm Oxford Biomedica has announced that Phase II trials of its bowel cancer vaccine, Trovax are due to start.

The study will be funded by Cardiff University and Cancer Research Wales and will involve 54 patients with inoperable forms of the disease.

Stuart Naylor, Chief Scientific Officer at Oxford Biomedica, said: “We believe TroVax holds great promise in the treatment of colorectal cancer and very much look forward to working with our colleagues at Cardiff University.”